Pacira BioSciences Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
712
- Stock Symbol
-
PCRX
- Investments
-
12
- Share Price
-
$15.89
- (As of Thursday Closing)
Pacira BioSciences General Information
Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Contact Information
Website
www.pacira.comCorporate Office
- 5401 West Kennedy Boulevard Lincoln Center
- Suite 890
- Tampa, FL 33609
- United States
Corporate Office
- 5401 West Kennedy Boulevard Lincoln Center
- Suite 890
- Tampa, FL 33609
- United States
Pacira BioSciences Timeline
Pacira BioSciences Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.89 | $15.53 | $11.16 - $35.95 | $733M | 46.1M | 1.3M | $1.37 |
Pacira BioSciences Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,587,572 | 1,921,916 | 2,264,418 | 2,540,944 |
| Revenue | 690,310 | 674,978 | 666,823 | 541,533 |
| EBITDA | 171,149 | 143,167 | 135,837 | 113,052 |
| Net Income | 63,593 | 41,955 | 15,909 | 41,980 |
| Total Assets | 1,646,820 | 1,574,386 | 1,681,200 | 2,075,353 |
| Total Debt | 648,595 | 586,044 | 763,394 | 1,128,848 |
Pacira BioSciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pacira BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Pacira BioSciences Comparisons
Industry
Financing
Details
Pacira BioSciences Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| Alexza Pharmaceuticals | Formerly VC-backed | Mountain View, CA | ||||
| Abbott India | Corporation | Mumbai, India | ||||
| GlaxoSmithKline Consumer Nigeria | Corporation | Lagos, Nigeria | ||||
| Audion Therapeutics | Venture Capital-Backed | Amsterdam, Netherlands |
Pacira BioSciences Patents
Pacira BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240156799-A1 | Uses of bupivacaine multivesicular liposomes as stellate ganglion block for treating anxiety disorders and traumatic brain injury | Pending | 10-Nov-2022 | ||
| US-11918565-B1 | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions | Active | 03-Nov-2022 | ||
| US-20240148967-A1 | Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions | Pending | 03-Nov-2022 | ||
| US-20240216348-A1 | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions | Pending | 03-Nov-2022 | ||
| US-20230277516-A1 | Uses of bupivacaine multivesicular liposomes as stellate ganglion block | Pending | 24-Feb-2022 | A61P23/02 |
Pacira BioSciences Executive Team (17)
| Name | Title | Board Seat |
|---|---|---|
| Frank Lee | Chief Executive Officer & Board Member | |
| Lauren Riker | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Daryl Gaugler | Chief Operating Officer, Operations | |
| Ron Ellis | Chief Strategy Officer | |
| Kristen Williams | Chief Administrative Officer, Administration & Secretary, Administration |
Pacira BioSciences Board Members (17)
| Name | Representing | Role | Since |
|---|---|---|---|
| Abraham Ceesay | Self | Board Member | |
| Alethia Young | Self | Board Member | |
| Andreas Wicki Ph.D | HBM Healthcare Investments | Board Member and Member of the Audit Committee | |
| Christopher Christie JD | Self | Board Member | |
| Frank Lee | Pacira BioSciences | Chief Executive Officer & Board Member |
Pacira BioSciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pacira BioSciences Investments & Acquisitions (12)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Spine BioPharma | 08-Feb-2023 | Drug Discovery | |||
| CarthroniX | 22-Apr-2022 | Drug Discovery | |||
| Genascence | 07-Jan-2022 | Biotechnology | |||
| Coda Biotherapeutics | 02-Dec-2021 | Drug Discovery | |||
| Flexion Therapeutics | 19-Nov-2021 | Merger/Acquisition | Pharmaceuticals |
Pacira BioSciences ESG
Risk Overview
Risk Rating
Updated May, 15, 2024
27.74 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Pharmaceuticals
Subindustry
of 446
Rank
Percentile
Pacira BioSciences Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Coda Biotherapeutics | 02-Dec-2021 | Completed |
|
||
| TELA Bio | 25-Oct-2017 | Completed |
|
||
| TELA Bio | 27-Jan-2017 | Early Stage VC | Completed |
|
Pacira BioSciences FAQs
-
When was Pacira BioSciences founded?
Pacira BioSciences was founded in 2006.
-
Who is the CEO of Pacira BioSciences?
Frank Lee is the CEO of Pacira BioSciences.
-
Where is Pacira BioSciences headquartered?
Pacira BioSciences is headquartered in Tampa, FL.
-
What is the size of Pacira BioSciences?
Pacira BioSciences has 712 total employees.
-
What industry is Pacira BioSciences in?
Pacira BioSciences’s primary industry is Pharmaceuticals.
-
Is Pacira BioSciences a private or public company?
Pacira BioSciences is a Public company.
-
What is Pacira BioSciences’s stock symbol?
The ticker symbol for Pacira BioSciences is PCRX.
-
What is the current stock price of Pacira BioSciences?
As of 03-Oct-2024 the stock price of Pacira BioSciences is $15.89.
-
What is the current market cap of Pacira BioSciences?
The current market capitalization of Pacira BioSciences is $733M.
-
What is Pacira BioSciences’s current revenue?
The trailing twelve month revenue for Pacira BioSciences is $690M.
-
Who are Pacira BioSciences’s competitors?
Pfizer Pakistan, Alexza Pharmaceuticals, Abbott India, GlaxoSmithKline Consumer Nigeria, and Audion Therapeutics are some of the 19 competitors of Pacira BioSciences.
-
What is Pacira BioSciences’s annual earnings per share (EPS)?
Pacira BioSciences’s EPS for 12 months was $1.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
